The next generation
of liquid biopsy

EVolvDx develops fully automated multi-omic diagnostic solutions powered by Extracellular Vesicles and cell-free DNA.

Created by pioneers in Extracellular Vesicle (EV) diagnostics, EVolvDx combines scalable automation with rich multi-omic molecular profiling to unleash a new generation of liquid biopsy diagnostics.

One sample. Multiple layers of biological insight.

Detailed diagram of a virus showing the viral envelope, RNA inside, and various functional features including transcription, mutation, DNA integration, and long-term monitoring.

Richer biological insight from every sample.

Our Science

Richer Biology

Molecular profiling from EVs capture changes from living cells. Optional cfDNA co-isolation when it adds value

Scalable Automation

High-throughput, end-to-end workflows for clinical testing

Al-Powered Discovery

Multi-omic data and machine learning for better biomarkers

Built for Impact

Scalable diagnostics designed for real-world clinical implementation

Our validated signatures drive clinical decisions, while the underlying transcriptome provides a scalable, cost-effective platform for continuous biomarker discovery and the development of multiple tests on a single lab infrastructure.

For decades, molecular diagnostics have relied on measuring a small number of predefined biomarkers. Our advances in EV isolation, next-generation sequencing, automation, and AI now make it possible to profile the entire transcriptome (and cfDNA when it adds value) from every sample, capturing tens of thousands of molecular signals and revealing biology that targeted approaches miss.

One sample. One assay. The complete molecular picture.

Why now: A convergence moment in diagnostics

  • Close-up of a laboratory or industrial machine with rows of clear test tubes or vials held in metal holders.

    Sequencing economics have fundamentally changed

    Transcriptome-scale EV-RNA + cfDNA analysis is now economically viable at volume. The power of EV transcriptomics can finally be deployed at scale.

  • AI unlocks the data advantage

    AI unlocks the data advantage

    Multi-omic datasets (EV-RNA + cfDNA) can be mined with AI/ML to discover higher-performance signatures. More data → better models → better tests — a compounding flywheel.

  • Leveraged by AI

    Automation changes the math

    High-throughput automated workflows make precision diagnostics scalable, reproducible, and cost-efficient — allowing one platform to support multiple clinical indications.

Our Mission

EVolvDx™ is building a next-generation liquid biopsy platform powered by complementary EV-RNA* and cfDNA** biology to deliver more accurate, scalable precision diagnostics and improve patient outcomes.

* Extracellular Vesicle RNA
** Cell-free DNA

Built by the team behind the world’s first Exosome-based diagnostic tests, EVolvDx is advancing automation, scalability, and data-driven biomarker discovery for the next generation of precision medicine.